The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Open accessAbstract
Myc amplification may transcriptionally regulate immune inhibition-associated molecules such as CD47 and PD-L1 in a mouse model of T cell acute lymphoblastic leukemia (12).In addition, Kras G12D can cause an increase in expression of the inflammatory cytokine GM-CSF in a mouse model of pancreatic neoplasia (13).Loss of P53 function activates the JAK2-STAT3 signaling pathway and promotes pancreatic tumor growth (14), and mutant P53 prolongs NF-kB activation and increases colorectal tumor incidence in a mouse model (15).These studies reveal a general mechanistic connection between cancer driver mutation-related inflammation and cancer progression in different model systems.However, the link among cancer driver gene mutations, T cell immunity, and immunotherapy response has not been established in patients with cancer.Thus, we have attempted to explore whether cancer genetic driver mutation(s) are capable of directly driving cancer immune phenotype, contributing to IFN signature and T cell immunity, and affecting immunotherapy response in models and in patients with cancer.Given that the most recurrent cancer driver genetic mutations, including MYC, APC, TP53, and KRAS, have been examined, in this work we focused our studies on the cancer driver epigenetic mutations such as ARID1A mutations (16)(17)(18)(19).ARID1A belongs to the SWI/SNF complex and is a core member of the ATP-dependent polymorphic BRG/BRM-associated factor (BAF) chromatin remodeling unit.SWI/SNF complex mutations Whether mutations in cancer driver genes directly affect cancer immune phenotype and T cell immunity remains a standing question.ARID1A is a core member of the polymorphic BRG/BRM-associated factor chromatin remodeling complex.ARID1A mutations occur in human cancers and drive cancer development.Here, we studied the molecular, cellular, and clinical impact of ARID1A aberrations on cancer immunity.We demonstrated that ARID1A aberrations resulted in limited chromatin accessibility to IFN-responsive genes, impaired IFN gene expression, anemic T cell tumor infiltration, poor tumor immunity, and shortened host survival in many human cancer histologies and in murine cancer models.Impaired IFN signaling was associated with poor immunotherapy response.Mechanistically, ARID1A interacted with EZH2 via its carboxyl terminal and antagonized EZH2-mediated IFN responsiveness.Thus, the interaction between ARID1A and EZH2 defines cancer IFN responsiveness and immune evasion.Our work indicates that cancer epigenetic driver mutations can shape cancer immune phenotype and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 4×
“POLE mutations (48) and PIK3CA mutations (16, 17, 49) frequently co-occur with ARID1A mutations (32, 48).”
BackgroundResultInfluentialMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Type-I and type-II IFN gene signatures correlate with clinical responses to cancer immunotherapy (4-7), biological antibody therapy, chemotherapy, and radiation therapy (8-10).”
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“4 Introduction Tumor infiltrating T cells are positively associated with patient survival in many types of human cancer (1-3).”
BackgroundZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 3×
“ARID1A mutations were also associated with poor survival in patients with hepatocellular carcinoma (Figure 8C), hepatobiliary cancer (Figure 8D), and pancreatic cancer (Figure 8E) (46) in the MSKCCIMPACT cohort.”
BackgroundResultInfluential
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Interferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Targeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Metadata
- Authors
- Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., Wei, S., Zhou, J., Li, G., Jing, X., Vatan, L., Zhao, L., Bitler, B., Zhang, R., Cho, K. R., Dou, Y., Kryczek, I., Chan, T. A., Huntsman, D., Chinnaiyan, A. M., & Zou, W.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-04-20
- Volume
- 130
- Issue
- 5
- Pages
- 2712-2726
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3004964052
- Cited by
- 191
- References
- 30
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. https://app.cochat.ai/papers/10.1172/jci134402
- The paper
- Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., Wei, S., Zhou, J., Li, G., Jing, X., Vatan, L., Zhao, L., Bitler, B., Zhang, R., Cho, K. R., . . . Zou, W. (2020). Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci134402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.